192 related articles for article (PubMed ID: 36045346)
21. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.
Bard JD; Gelebart P; Anand M; Amin HM; Lai R
Leukemia; 2008 Aug; 22(8):1595-603. PubMed ID: 18509351
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.
Zhang J; Wang P; Wu F; Li M; Sharon D; Ingham RJ; Hitt M; McMullen TP; Lai R
Cell Signal; 2012 Apr; 24(4):852-8. PubMed ID: 22155737
[TBL] [Abstract][Full Text] [Related]
24. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
Staber PB; Vesely P; Haq N; Ott RG; Funato K; Bambach I; Fuchs C; Schauer S; Linkesch W; Hrzenjak A; Dirks WG; Sexl V; Bergler H; Kadin ME; Sternberg DW; Kenner L; Hoefler G
Blood; 2007 Nov; 110(9):3374-83. PubMed ID: 17690253
[TBL] [Abstract][Full Text] [Related]
25. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
26. C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.
Anastasov N; Bonzheim I; Rudelius M; Klier M; Dau T; Angermeier D; Duyster J; Pittaluga S; Fend F; Raffeld M; Quintanilla-Martinez L
Haematologica; 2010 May; 95(5):760-7. PubMed ID: 20015877
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
[TBL] [Abstract][Full Text] [Related]
28. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.
Babin L; Darchen A; Robert E; Aid Z; Borry R; Soudais C; Piganeau M; De Cian A; Giovannangeli C; Bawa O; Rigaud C; Scoazec JY; Couronné L; Veleanu L; Cieslak A; Asnafi V; Sibon D; Lamant L; Meggetto F; Mercher T; Brunet E
Mol Cancer; 2022 Mar; 21(1):65. PubMed ID: 35246138
[TBL] [Abstract][Full Text] [Related]
29. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
[TBL] [Abstract][Full Text] [Related]
30. KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth.
Hwang J; Song I; Lee K; Kim HR; Hong EH; Hwang JS; Ahn SH; Lee J
Invest New Drugs; 2020 Oct; 38(5):1282-1291. PubMed ID: 31956933
[TBL] [Abstract][Full Text] [Related]
31. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
[TBL] [Abstract][Full Text] [Related]
32. STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.
Spaccarotella E; Pellegrino E; Ferracin M; Ferreri C; Cuccuru G; Liu C; Iqbal J; Cantarella D; Taulli R; Provero P; Di Cunto F; Medico E; Negrini M; Chan WC; Inghirami G; Piva R
Haematologica; 2014 Jan; 99(1):116-24. PubMed ID: 23975180
[TBL] [Abstract][Full Text] [Related]
33. SBNO2 is a critical mediator of STAT3-driven hematological malignancies.
Brandstoetter T; Schmoellerl J; Grausenburger R; Kollmann S; Doma E; Huuhtanen J; Klampfl T; Eder T; Grebien F; Hoermann G; Zuber J; Mustjoki S; Maurer B; Sexl V
Blood; 2023 Apr; 141(15):1831-1845. PubMed ID: 36630607
[TBL] [Abstract][Full Text] [Related]
34. The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.
George SK; Vishwamitra D; Manshouri R; Shi P; Amin HM
Oncotarget; 2014 Jul; 5(14):5750-63. PubMed ID: 25026277
[TBL] [Abstract][Full Text] [Related]
35. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
36. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
[TBL] [Abstract][Full Text] [Related]
38. STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma.
Prutsch N; He S; Berezovskaya A; Durbin AD; Dharia NV; Maher KA; Matthews JD; Hare L; Turner SD; Stegmaier K; Kenner L; Merkel O; Look AT; Abraham BJ; Zimmerman MW
Cell Rep Med; 2024 Mar; 5(3):101472. PubMed ID: 38508140
[TBL] [Abstract][Full Text] [Related]
39. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
[TBL] [Abstract][Full Text] [Related]
40. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
